• is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.


  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.


I have read and understood the above

Clinical management of CF » Established therapies

Established therapies

1 of 3

As CF is a multi-system disease, an aggressive combination of specific therapies is required to treat the disease symptoms. Such interventions include therapies to challenge CF-associated malnutrition, diabetes, lung disease and systemic inflammation.

> Click the Next button to find out more about respiratory and nutritional therapies.

1 of 3
  1. Flume PA et al. Am J Respir Crit Care Med 2009;180:802–8
  2. Bilton D et al. J Cyst Fibros 2001;10(Suppl 2):S79–81
  3. Pisi G et al. Acta Biomed 2009;80:102–6
  4. Dwyer TJ et al. Curr Opin Pulm Med 2011;17:455–60
  5. Balfour-Lynn IM et al. Am J Respir Crit Care Med 2006;173:1356–62
  6. Lands LC. J Pediatr 2007;151:249–54
  7. Lands LC. Cochrane Database Syst Rev. 2007;4:CD001505
  8. Balsamo R et al. Eur Respir Rev 2010;19:127–33
  9. Elkins M et al. Cochrane Database Syst Rev. 2012;15:CD008816
  10. Smyth A et al. Cochrane Library, Issue 3. Chichester, UK. John Wiley & Sons Ltd 2004
  11. Smyth T et al. Arch Dis Child Educ Pract Ed 2005;90:1–6
  12. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group 2009 ISBN 0-9548511-3-7
  13. Wilms EB et al. Pediatr Pulmonol 2012;47:658–65
  14. O’Sullivan B et al. Lancet 2009;373:1891–904
  15. Anon. Bethesda, MD. Cystic Fibrosis Foundation Patient Registry 2007
  16. Ratjen FA. Respir Care 2009;54:595–605